Compare Repligen Corporation Common Stock (RGEN) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Global X Uranium ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Global X Uranium ETF trades at $35.14 (market cap $5.50B). The key difference: Repligen Corporation Common Stock is far larger — about 2× Global X Uranium ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Global X Uranium ETF for 64 Days on average.
| RGEN | URA | |
|---|---|---|
Market Cap | $11.14B | $5.50B |
Volume | 1,259,263 | 3,413,221 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $194.57 | $61.81 |
52-Week Low | $102.87 | $35.54 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
URA (Global X Uranium ETF) trades at $37.38, down 0.9% with a bearish technical signal from moving averages. The ETF provides diversified exposure to uranium miners and nuclear energy companies amid growing global nuclear adoption. Recent news highlights nuclear energy's role in meeting AI power demand and government support for reactor development. Key holdings include Cameco (over 20%) and Sprott Physical Uranium Trust (nearly 6%).
Outlook remains mixed with strong long-term nuclear demand drivers offset by recent sector volatility. Investment opportunity lies in nuclear's capacity factor advantages and policy support, while risks include uranium price fluctuations and concentrated holdings. The ETF's 18.9% correction presents potential entry point for thematic investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
